Lizomac

Linezolid

Treatment option: Community Acquired Pneumonia, Infectious Diseases, Infection, Infection,Soft Tissue, Pneumonia, Hospital Acquired Pneumonia

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lizomac

What Is Lizomac? (Identity and General Purpose)

This section provides a structured, authoritative overview of the medicine Lizomac (Linezolid), covering its core identity, classification, and general function.

Property	Description
Active Ingredient	Linezolid
Form	Tablet, Injection, Oral Suspension
Pharmacological Class	Oxazolidinone Antibiotic
Common Use	Treating Bacterial Infections
Origin	Synthetic (Acetamide Derivative)

What Type of Medicine Is Lizomac and Its Active Ingredient?

Lizomac is a specific trade name for the active ingredient Linezolid (INN), a prescription-only synthetic antibacterial agent. It is classified as an antibiotic belonging to the unique family of oxazolidinones, positioning it as a modern agent used to combat pathogenic microorganisms. Linezolid was established as a new class of antibacterial for managing serious infections.

Linezolid is defined as a synthetic acetamide derivative, meaning its origin is entirely manufactured rather than being derived from natural sources. It is consistently administered as a single-ingredient product, and this structure was specifically engineered to overcome common bacterial resistance mechanisms, granting it a critical role in infectious disease management.

General Purpose and Anti-Infective Function

The primary purpose of Lizomac is to act as an effective anti-infective agent for treating serious bacterial infections, particularly those caused by resistant Gram-positive pathogens. A key differentiating feature is its high oral bioavailability, which allows patients often to transition efficiently from hospital-based intravenous injection to oral forms like the tablet or oral suspension, providing continuity of care.

Lizomac functions primarily by acting as a protein synthesis inhibitor, a mechanism clinically recognized for stopping the bacteria from multiplying. It achieves this by selectively preventing the necessary formation of the initiation complex on the bacteria's ribosome. This bacteriostatic action limits the infection's spread, supporting the patient's immune system in clearing the pathogen.

What side effects are possible with Lizomac?

Possible Side Effects and Safety Information

The safety profile of Lizomac (linezolid) is officially documented by governmental regulatory agencies, detailing adverse reactions by frequency and physiological system.

Adverse reactions are classified into categories such as Common (occurring in 1 in 100 to less than 1 in 10 patients) and Uncommon (occurring in 1 in 1,000 to less than 1 in 100 patients).

Key adverse reactions involve several System-Organ Classes, including the Gastrointestinal System (e.g., diarrhea, nausea, headache), the Blood and Lymphatic System (e.g., anemia, myelosuppression), and the Nervous System (e.g., dizziness, taste perversion).

Serious Adverse Reactions and Safety Patterns

The label documents several serious adverse reactions, including Myelosuppression (which encompasses thrombocytopenia, leukopenia, and severe anemia), Lactic Acidosis, and Serotonin Syndrome. Cases of Peripheral and Optic Neuropathy have also been reported.

Regulatory documents explicitly state that the risk of certain serious effects, notably myelosuppression and neuropathy, increases with the duration of treatment, particularly when Lizomac is administered for longer than 28 days. This establishes an exposure-dependent safety pattern.

Safety Considerations

Lizomac is classified as a reversible, nonselective Monoamine Oxidase Inhibitor (MAOI). This pharmacological property is a high-level safety constraint, as co-administration with other serotonergic agents may lead to serious consequences like Serotonin Syndrome. Specific safety notes also exist for certain populations, such as elderly patients and those with severe renal impairment, who may experience an increased incidence of effects like thrombocytopenia.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Lizomac

Overdose Scope

Documented overdose presentations: The primary concerns in Linezolid (Lizomac) overdose relate to severe toxicity, including signs of Lactic Acidosis (unexplained acidosis, low bicarbonate level, recurrent nausea/vomiting) and Serotonin Syndrome (rigidity, hyperthermia, mental status changes). Nonclinical studies reported signs such as ataxia and tremors at high exposures. Physiological systems affected (as stated in label): The Central Nervous System (CNS) and metabolic system are affected, with documented risks including Convulsions (Seizures). Dose-related or exposure-related factors (if applicable): Nonclinical toxicity signs are linked to exposures significantly higher than therapeutic levels. Population-specific overdose notes (if applicable): Patients with severe renal impairment may have a higher risk of toxicity, such as thrombocytopenia.

Emergency-response statements (as written in official documents):

When immediate medical help is required (label-derived phrasing only): Immediate medical evaluation is required for patients who develop unexplained acidosis, low bicarbonate level, or persistent nausea and vomiting. Emergency services must be contacted immediately if a patient collapses, has a seizure, or cannot be awakened.

Overdose Classifications (High-Level)

Severity classification (as defined in official documents): The profile is classified by the risk of life-threatening or severe outcomes requiring urgent medical intervention. Regulatory basis (EMA / FDA / etc.): Based on information from government regulatory authorities (e.g., FDA Prescribing Information, SmPCs, NIH/MedlinePlus). Overdose-context constraints (as defined in official documents): No specific antidote is known for Lizomac overdose.

Resulting overdose structure

Official overdose statements:

No specific antidote is known for Lizomac overdose.
Treatment is strictly symptomatic and supportive.
Hemodialysis is documented as a procedure that can remove approximately 30% of the drug.
Immediate medical evaluation is required upon developing signs of Lactic Acidosis or other severe symptoms.

Connection to the overall overdose profile (2–4 sentences): Regulatory documents define the Lizomac overdose profile by focusing on the recognition of severe systemic toxicity, such as Lactic Acidosis and Seizures, which necessitate immediate medical help. Given that no specific antidote is known, treatment is entirely centered on providing supportive care. The regulatory guidance establishes a clear, non-advisory threshold for contacting emergency services based on specific life-threatening clinical signs.

Therapeutic Uses of Lizomac

What Lizomac Treats: Main Uses and Benefits

Lizomac, containing linezolid, is an antibacterial agent applied in addressing certain bacterial infections caused by susceptible Gram-positive bacteria. Its therapeutic use is relevant in conditions characterized by periods of heightened symptoms that involve inflammatory or irritative processes. The medicine is commonly used to help with symptom clusters that may become intense or disruptive in conditions presenting with systemic or localized discomfort, including: nosocomial pneumonia, community-acquired pneumonia, and complicated skin and soft tissue infections.

It is often used when symptoms intensify and supportive relief is needed, including for infections involving organisms such as methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant Enterococcus faecium. Lizomac generally helps support the patient during difficult episodes by easing distress and contributes to easing the overall symptom load. It may assist with maintaining functional stability during these episodes.

“Applied in clinical settings that involve acute or unstable symptom patterns.”

Quick Fact: Supports symptoms that create noticeable physiological strain. Lizomac helps improve day-to-day comfort during symptomatic periods.

Eligibility and Restrictions for Use

Who Can and Cannot Use Lizomac?

The population eligibility for Lizomac (Linezolid) is strictly defined by regulatory documentation.

Contraindicated Populations

The medicine is contraindicated and must not be used by patients with a known hypersensitivity to the drug or its components. It is also prohibited for patients who are currently taking or have taken any Monoamine Oxidase Inhibitor (MAOI), such as phenelzine or selegiline, within the last two weeks.

Restricted and Conditional Use

Organ Function and Comorbidities: Use is conditional for patients with severe renal impairment or moderate to severe hepatic impairment, and is permitted only when the anticipated benefit outweighs the theoretical risk. The medicine is restricted in patients with uncontrolled hypertension, pheochromocytoma, or carcinoid syndrome unless facilities for close monitoring are available.

Age and Reproductive Status: Use is established for adults and older adults. However, European regulatory guidance states that use in children under 18 years is not recommended due to insufficient data. Pregnancy use is restricted unless clearly necessary, and breastfeeding must be discontinued throughout treatment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Lizomac (Linezolid) is primarily defined by its documented effect as a reversible, non-selective Monoamine Oxidase Inhibitor (MAOI). This classification dictates mandatory restrictions and requirements for co-administration with other substances.

Official Contraindications and Cautions

Category	Interacting Agents	Regulatory Requirement
Absolute Contraindication	Monoamine Oxidase Inhibitors (MAOIs)	Prohibited co-administration; mandatory two-week washout period.
Serotonergic Risk	SSRIs, SNRIs, Triptans, Opioids (e.g., tramadol)	Use generally avoided or requires close monitoring for Serotonin Syndrome.
Adrenergic Risk	Sympathomimetics (e.g., pseudoephedrine), Vasopressors (e.g., dopamine)	Requires monitoring for potential elevation of blood pressure.

Mechanism of Action

How Lizomac Works

Linezolid's action is defined by the mechanism of protein synthesis inhibition, alongside a separate modulation of host enzyme activity.

Unique Blockade of Protein Synthesis Initiation

This mechanism focuses on the bacterial ribosome. Linezolid acts by binding to the 23S ribosomal RNA of the 50S subunit, physically blocking the formation of the 70S initiation complex required for protein synthesis. This early molecular intervention immediately arrests pathogen proliferation, which leads to the physiological outcome of suppressed bacterial multiplication.

Species-Specific Growth Inhibition

This describes the physiological consequence of the blockade. The mechanism primarily induces bacteriostasis (growth arrest) against certain key Gram-positive bacteria (staphylococci and enterococci). This effect maintains a physiological dependency on the host's mechanisms for pathogen removal. Against other strains like streptococci, the same mechanism results in bactericidal action (cell death), demonstrating a species-dependent modulation of pathogen viability.

Secondary Modulation of Host Neurotransmitter Metabolism

This addresses a distinct pharmacological action on the human host. Linezolid is a reversible inhibitor of Monoamine Oxidase (MAO) enzymes. By engaging this enzyme system, the drug reduces the metabolic breakdown of host monoamines like serotonin and norepinephrine, leading to elevated neurotransmitter levels in the body. This modulation of host enzyme activity contributes to the full pharmacological profile.

Dosage and Administration Information

Lizomac (Linezolid) is an oxazolidinone-class antibacterial prescribed for certain serious infections, such as nosocomial pneumonia and complicated skin and skin structure infections, caused by susceptible bacteria. It is important to adhere strictly to your healthcare provider’s instructions when taking this medication.

Administration and Dosing

Oral Formulations: The oral tablets or suspension are typically taken twice a day (every 12 hours). Linezolid is rapidly and extensively absorbed and may be administered with or without food.
Tablets: Swallow the tablet whole with water. Do not crush or chew the tablet.
Oral Suspension: Before each use, gently mix the liquid by turning the bottle upside down three to five times; do not shake vigorously. Use a marked measuring device, not a household spoon, to ensure the correct dose. Discard any unused oral suspension 21 days after preparation.
Completing the Course: Continue taking the medication for the full duration prescribed by your doctor, even if your symptoms improve. Stopping the antibiotic early may lead to the return of infection or the development of drug-resistant bacteria.

Important Considerations

Tyramine Restriction: Linezolid is a reversible, non-selective monoamine oxidase inhibitor (MAOI), meaning it can interact with high-tyramine foods, potentially causing a temporary increase in blood pressure. While on this medication, you should avoid or limit the consumption of foods and drinks that are rich in tyramine, such as aged cheeses, yeast extracts, fermented meats, tap beers, and red wines.
Missed Dose: If you miss a dose, take it as soon as you remember. If it is almost time for your next scheduled dose, skip the missed one and continue with your regular schedule. Do not take a double dose to make up for a missed one.

Recent Clinical Evidence

Research Focus and Findings

Recent clinical evidence for Lizomac (linezolid) primarily focuses on its use in treating serious infections caused by specific Gram-positive bacteria, particularly those resistant to other antibiotics, such as Methicillin-Resistant Staphylococcus aureus (MRSA) and Vancomycin-Resistant Enterococcus (VRE).

Studies evaluated the drug's effect on inhibiting bacterial protein synthesis, a mechanism distinct from many other antibiotics. This research area confirms its bacteriostatic activity against staphylococci and enterococci, and bactericidal activity against most isolates of streptococci.

Phase III Trial Data: Comparative, randomized controlled trials (RCTs) have evaluated Lizomac against glycopeptide antibiotics (like vancomycin) and beta-lactam antibiotics. Findings indicated that the treatment was comparable or non-inferior to these comparator drugs in the management of nosocomial pneumonia and complicated skin and soft tissue infections (SSTIs).

Studies on Safety and Tolerability

Clinical trials have explored the drug’s tolerability when used for up to 28 days. Adverse events reported were typically mild to moderate in intensity and included diarrhea, nausea, and headache. Discontinuations due to adverse events, serious adverse events, and mortality rates were generally similar between the Lizomac and comparator groups in the Phase III trials.

Hematologic Monitoring

Research has explored the potential for reversible thrombocytopenia (low platelet count) and anemia, particularly when therapy extended beyond 14 days. These studies emphasize the importance of regular blood counts for patients receiving prolonged treatment.

Drug Interaction Studies

Studies have confirmed that Lizomac is a reversible, nonselective monoamine oxidase (MAO) inhibitor. Because of this, research highlights the need for caution and dietary restrictions (e.g., foods high in tyramine) and careful monitoring when Lizomac is co-administered with certain serotonergic or adrenergic agents.

Key Studies & References

Linezolid - StatPearls (NIH Bookshelf)

Frequently Asked Questions (FAQ)

Common questions about Lizomac (FAQ)

Q: What is Lizomac (Linezolid) used for?

Lizomac (Linezolid) is an antibiotic used to treat serious bacterial infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). It is often used for:

Pneumonia (specifically nosocomial or community-acquired)
Certain skin and soft tissue infections

It is part of a class of antibiotics known as oxazolidinones.

Q: How does Lizomac (Linezolid) work?

Lizomac works by stopping bacteria from growing. It does this by interfering with the production of proteins essential for the bacteria's survival and replication. Specifically, it binds to a site on the bacterial ribosome, preventing the assembly of the protein-making machinery. This action makes it effective against bacteria that are resistant to many other types of antibiotics.

Q: Can Lizomac (Linezolid) be used to treat COVID-19?

No, Lizomac (Linezolid) is not used to treat COVID-19. COVID-19 is caused by a virus, and Lizomac is an antibiotic designed to treat infections caused by bacteria. Antibiotics are ineffective against viral infections like COVID-19. It may be used if a patient with COVID-19 develops a secondary bacterial infection that is susceptible to Linezolid, but it is not a direct treatment for the viral disease itself.

Q: What is Serotonin Syndrome, and is it a risk with Lizomac (Linezolid)?

Serotonin Syndrome is a potentially serious side effect caused by excessive levels of serotonin in the body's nervous system. It is a known risk with Lizomac (Linezolid) because Lizomac is a weak monoamine oxidase inhibitor (MAOI), which can increase serotonin levels. The risk is significantly higher when Lizomac is taken alongside other medications that also increase serotonin, such as:

SSRIs (e.g., fluoxetine, sertraline)
SNRIs (e.g., venlafaxine)
Tricyclic antidepressants
Triptans (for migraines)

Symptoms of Serotonin Syndrome can include:

Agitation or restlessness
Rapid heart rate
High body temperature
Twitching muscles or rigid muscles
Nausea and diarrhea

It is crucial to inform a healthcare provider of all medications and supplements being taken before starting Lizomac to manage this risk.

Q: Does Lizomac (Linezolid) have an effect on blood counts?

Yes, Lizomac (Linezolid) can affect blood cell counts, particularly with extended use (often defined as treatment longer than 28 days). The primary blood-related side effects include:

Thrombocytopenia (low platelet count), which increases the risk of bleeding or bruising.
Anemia (low red blood cell count).
Neutropenia (low white blood cell count).

Due to these risks, regular blood tests are often required for patients receiving Lizomac, especially those on long-term therapy, to monitor blood cell levels.

How should Lizomac be stored and disposed of?

How to Store and Dispose of Lizomac (Linezolid Injection)

The storage and disposal of Lizomac (Linezolid Injection) must follow the specific requirements outlined in official regulatory labeling.

Storage Conditions

Item	Requirement
Temperature	Store at room temperature.
Protection	Must be protected from freezing.
Packaging	Keep the container in the overwrap until ready to use.
Integrity Check	Inspect for particulate matter and leaks prior to use; discard if leaks are detected, as sterility may be impaired.
Stability Note	A yellow color may intensify over time, but this does not adversely affect potency.

Disposal Instructions

Lizomac is supplied as a single-dose ready-to-use container. Any unused portion of the solution remaining after administration must be discarded. There are no specific hazardous waste disposal classifications stated in the product label.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.